Immuneering Corp (IMRX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
IMRX currently has 64.7M outstanding shares. with limited dilution risk as only 7.02M additional shares (10.9%) are authorized for issuance. The company has significantly diluted shareholders by 101.75% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 15, 2026 |
10-Q filing | 64.7M shares outstanding |
65M | 7M |
| Nov 12, 2025 |
10-Q filing | 64.6M shares outstanding |
65M | 7M |
| Sep 25, 2025 |
8-K filing: Immuneering Corporation executed an underwriting agreement for a public offering of 18,959,914 shares of Class A common stock at $9.23 per share and a concurrent private placement to Aventis Inc. for 2,708,559 shares of Class A common stock at the same price. ($200.0M proceeds) |
36M | 7M |
| Aug 13, 2025 |
10-Q filing | 36.0M shares outstanding |
36M | 7M |
| May 05, 2025 |
10-Q filing | 35.5M shares outstanding |
36M | 7M |
| Mar 20, 2025 |
10-K filing | 35.9M shares outstanding |
36M | 7M |
| Nov 13, 2024 |
10-Q filing | 29.8M shares outstanding |
30M | 7M |
| Aug 06, 2024 |
10-Q filing | 29.7M shares outstanding |
30M | 7M |
| May 07, 2024 |
10-Q filing | 29.4M shares outstanding |
29M | 7M |
| Mar 01, 2024 |
10-K filing | 28.4M shares outstanding |
28M | 7M |
| Nov 09, 2023 |
10-Q filing | 29.3M shares outstanding |
29M | 7M |
| Aug 03, 2023 |
10-Q filing | 28.6M shares outstanding |
29M | 7M |
| May 04, 2023 |
10-Q filing | 26.4M shares outstanding |
26M | 7M |
| Apr 19, 2023 |
8-K filing: Immuneering Corporation entered into an underwriting agreement for the public offering, issuance, and sale of 2,727,273 shares of Class A common stock at $11.00 per share, with expected net proceeds of approximately $27.8 million. ($30.0M proceeds) |
26M | 7M |
| Mar 06, 2023 |
10-K filing | 26.4M shares outstanding |
26M | 7M |
| Nov 10, 2022 |
10-Q filing | 26.4M shares outstanding |
26M | 7M |
| Aug 10, 2022 |
10-Q filing | 26.4M shares outstanding |
26M | 7M |
| Aug 10, 2022 |
S-3 filing: Immuneering Corporation files an S-3 to offer and sell up to $200,000,000 in the aggregate of Class A Common Stock, Preferred Stock, Debt Securities, Warrants, and Units from time to time in one or more offerings. |
26M | 7M |
| May 10, 2022 |
10-Q filing | 26.4M shares outstanding |
26M | 0 |
| Mar 10, 2022 |
10-K filing | 5.0M shares outstanding |
5M | 0 |
| Dec 22, 2021 |
8-K filing: Immuneering Corporation acquired BioArkive, Inc. for $8.75 million, paid through the issuance of 379,635 shares of Immuneering's Class A common stock. ($8.75M proceeds) |
5M | 0 |
| Nov 09, 2021 |
10-Q filing | 5.0M shares outstanding |
5M | 0 |
| Sep 09, 2021 |
10-Q filing | 5.0M shares outstanding |
5M | 0 |
| Jul 28, 2021 |
S-1/A filing: This is an S-1/A filing detailing other expenses of issuance and distribution, indemnification of directors and officers, and recent sales of unregistered securities. |
N/A | 0 |
| Jul 26, 2021 |
S-1/A filing: This is an S-1/A filing for an offering of Class A common stock underwritten by Morgan Stanley, Jefferies, Cowen, and Guggenheim Securities. |
N/A | 0 |
| Jul 09, 2021 |
S-1 filing: This is an S-1 filing for an initial public offering of Class A common stock underwritten by Morgan Stanley, Jefferies, Cowen, and Guggenheim Securities. |
N/A | 0 |